Neuro XPF is a sports supplements company specializing in the medicinal benefits of cannabinoids.
Neuro XPF (NXPF) makes and sells a full line of high-quality, certified-organic, hemp-derived CBD products that are THC-free. Over the past four years, we have developed proprietary products and established our initial business operations and distribution network.
Now, we are focused on:
Kyle John Turley is a former American football offensive lineman who played eight seasons in the National Football League.
Kyle suffered more than 100 concussions and other physical injuries during his eight-year NFL career. He retired with an addiction to opioids and was diagnosed with CTE, early-onset Alzheimer’s, as well as other serious neurological problems. Fortunately, Kyle discovered the healing, health-giving power of CBD (Cannabidiol).
Kyle founded the Gridiron Cannabis Coalition to use his story and those of other players to advance the idea of marijuana as a valid medicine for neurological conditions and other athletic injuries.
Neuro XPF has developed a unique, strong, and memorable brand presence in the CBD marketplace that is clearly differentiated from all competitors.
According to the Center for Neuro Skills, there are 6,849 ER visits for traumatic brain injuries (TBI) every day. Roughly 3.8 million traumatic brain injuries are sustained in sports and recreational activities each year and 13.5 million Americans have been disabled by acquired brain trauma (Brainline.org).
CBD is the only known chemical compound that can protect the brain against the debilitating effects of TBI. Research has shown that CBD may help heal brain tissue damaged by TBI and promote overall brain health. CBD is sport approved through the World Anti-Doping Agency, USADA, UFC, and the United States Olympic Comittee.
Within Sports Nurtrition, there are 175 million serious athletes and casual fitness and recreation consumers. According to MarketData Enterprises, the U.S market will reach $21 billion with an 8.4% compound annual growth rate (CAGR) through 2022.
For insomnia, MarketData Enterprises reported the U.S anti-insomnia med market topped $1.9 billion in 2019. Through 2023, the CAGR is an estimated $4.7 billion.
Pain and inflammation topped $19 billion in 2019 in the OTC pain med market, according to Future Market Insights. In addition, Allied Market Research reports that the anti-inflammatory med market will top $106 billion in 2020.
Lastly, chronic stress, anxiety, and depression have been labeled as a national epidemic for all ages and genders by Everyday Health. This will result in the U.S market for stress and anxiety meds to top $3.8 billion in 2020. According to Market Watch, The Psychiatric Association roughly 14 million individuals suffer from PTSD and around 8 million individuals suffer from depression.
There are more than 1,000 CBD brands currently in the marketplace. Most of those are mom-and-pop brands with dubious products and negligible market share. Serious brands are spending big to establish brand recognition and drive consumers to e-comm sites.
The top 10 CBD brands each command between 3% and 8% of online sales. Online sales are now subordinate to retail chains in big-box, pharmacy, grocery, convenience, etc. channels. CBD brands from companies that can leverage existing brick-and-mortar distribution networks are growing rapidly.
Neuro XPF is excited to be entering a $1,000,000.00 capital raise to fund near-term business, revenue, and profit growth. Neuro XPF develops, formulates, and distributes high-quality hemp CBD products that are safe, effective, and THC-free.
$150,000 will be allocated to marking and product sample production, an additional $150,000 is segmented for distribution and sales development. Forty-five percent will be allocated to inventory development. The remaining thirty-five percent will go towards growing product development and personnel.